Filing Details
- Accession Number:
- 0001209191-20-011258
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-20 18:37:40
- Reporting Period:
- 2020-02-18
- Accepted Time:
- 2020-02-20 18:37:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1394875 | M Gil Labrucherie | C/O Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco CA 94158 | Svp, Coo & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-18 | 5,938 | $22.35 | 253,221 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- This transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
Billionaire Hedge Funds
